VIATRIS INC. OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax
VIATRIS INC. (VTRS) reported OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax of -$100.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax · last filed 2026-08-06
- VIATRIS INC. oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for the quarter ending 2026-06-30 was -$100.00K, a 150.00% decline year-over-year.
- VIATRIS INC. oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for the quarter ending 2026-03-31 was -$500.00K, a 183.33% decline year-over-year.
- VIATRIS INC. oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for the quarter ending 2025-12-31 was -$100.00K.
- VIATRIS INC. oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for the quarter ending 2025-09-30 was $300.00K, a 72.73% decline year-over-year.
- VIATRIS INC. oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for fiscal 2025 was $1.00M.
- VIATRIS INC. oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for fiscal 2024 was -$100.00K, a 106.67% decline from fiscal 2023.
- VIATRIS INC. oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for fiscal 2023 was $1.50M.
- VIATRIS INC. oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for fiscal 2022 was -$2.80M.
| Period end | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax 3 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax 6 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax 9 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$100.00K 10-Q · filed 2026-08-06 | -$600.00K 10-Q · filed 2026-08-06 | -$700.00K derived: sum of 3 quarters · filed 2026-08-06 | -$400.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$500.00K 10-Q · filed 2026-05-07 | -$600.00K derived: sum of 2 quarters · filed 2026-05-07 | -$300.00K derived: sum of 3 quarters · filed 2026-05-07 | -$100.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $200.00K derived: sum of 2 quarters · filed 2026-02-26 | $400.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.00M 10-K · filed 2026-02-26 |
| 2025-09-30 | $300.00K 10-Q · filed 2025-11-06 | $500.00K derived: sum of 2 quarters · filed 2026-08-06 | $1.10M 10-Q · filed 2025-11-06 | $200.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $200.00K 10-Q · filed 2026-08-06 | $800.00K 10-Q · filed 2026-08-06 | -$100.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $600.00K 10-Q · filed 2026-05-07 | -$300.00K derived: sum of 2 quarters · filed 2026-05-07 | $800.00K derived: sum of 3 quarters · filed 2026-05-07 | $800.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$900.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $200.00K derived: sum of 2 quarters · filed 2026-02-26 | $200.00K derived: sum of 3 quarters · filed 2026-02-26 | -$100.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $1.10M 10-Q · filed 2025-11-06 | $1.10M derived: sum of 2 quarters · filed 2025-11-06 | $800.00K 10-Q · filed 2025-11-06 | $2.50M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-07 | -$300.00K 10-Q · filed 2025-08-07 | $1.40M derived: sum of 3 quarters · filed 2026-02-26 | $100.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$300.00K 10-Q · filed 2025-05-08 | $1.40M derived: sum of 2 quarters · filed 2026-02-26 | $100.00K derived: sum of 3 quarters · filed 2026-02-26 | $300.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $1.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $400.00K derived: sum of 2 quarters · filed 2026-02-26 | $600.00K derived: sum of 3 quarters · filed 2026-02-26 | $1.50M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$1.30M 10-Q · filed 2024-11-07 | -$1.10M derived: sum of 2 quarters · filed 2024-11-07 | -$200.00K 10-Q · filed 2024-11-07 | $500.00K derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $200.00K 10-Q · filed 2024-08-08 | $1.10M 10-Q · filed 2024-08-08 | $1.80M derived: sum of 3 quarters · filed 2025-02-27 | $1.00M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $900.00K 10-Q · filed 2024-05-09 | $1.60M derived: sum of 2 quarters · filed 2025-02-27 | $800.00K derived: sum of 3 quarters · filed 2025-02-27 | -$200.00K derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $700.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$100.00K derived: sum of 2 quarters · filed 2025-02-27 | -$1.10M derived: sum of 3 quarters · filed 2025-02-27 | -$2.80M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$800.00K 10-Q · filed 2023-11-08 | -$1.80M derived: sum of 2 quarters · filed 2023-11-08 | -$3.50M 10-Q · filed 2023-11-08 | |
| 2022-06-30 | -$1.00M 10-Q · filed 2023-08-07 | -$2.70M 10-Q · filed 2023-08-07 | ||
| 2022-03-31 | -$1.70M 10-Q · filed 2023-05-08 | |||
| 2021-12-31 | -$1.10M 10-K · filed 2024-02-28 | |||
| 2020-12-31 | $600.00K 10-K · filed 2023-02-27 | |||
| 2019-12-31 | $500.00K 10-K · filed 2022-02-28 | |||
| 2018-12-31 | -$100.00K 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |